Cargando…
Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor, epalrestat
AIMS: The long-term efficacy of epalrestat, an aldose reductase inhibitor, in improving subjective symptoms and nerve function was comprehensively assessed to identify patients with diabetic peripheral neuropathy who responded to epalrestat treatment. METHODS: Stratified analyses were conducted on d...
Autores principales: | Hotta, N, Kawamori, R, Atsumi, Y, Baba, M, Kishikawa, H, Nakamura, J, Oikawa, S, Yamada, N, Yasuda, H, Shigeta, Y |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2613255/ https://www.ncbi.nlm.nih.gov/pubmed/18644069 http://dx.doi.org/10.1111/j.1464-5491.2008.02490.x |
Ejemplares similares
-
Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy
por: Hotta, N, et al.
Publicado: (2012) -
Epalrestat, an aldose reductase inhibitor, in diabetic neuropathy: An Indian perspective
por: Sharma, S. R., et al.
Publicado: (2008) -
Aldose Reductase Drives Hyperacetylation of Egr-1 in Hyperglycemia and Consequent Upregulation of Proinflammatory and Prothrombotic Signals
por: Vedantham, Srinivasan, et al.
Publicado: (2014) -
Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG
por: Iyer, Sangeetha, et al.
Publicado: (2019) -
Amelioration of Bleomycin-induced Pulmonary Fibrosis of Rats by an Aldose Reductase Inhibitor, Epalrestat
por: Li, Xianwei, et al.
Publicado: (2015)